The Effect of DPP4 Inhibitor on Glycemic Variability in Patients with Type 2 Diabetes treated with twice-daily Premixed Human Insulin*
| العنوان: | The Effect of DPP4 Inhibitor on Glycemic Variability in Patients with Type 2 Diabetes treated with twice-daily Premixed Human Insulin* |
|---|---|
| المؤلفون: | Bik Kui Lau, Florence Tan, Xun Ting Tiong, Chin Voon Tong, Saravanan Vengadesa Pillai, Yueh Chien Kuan, Huai Heng Loh |
| المصدر: | Journal of the ASEAN Federation of Endocrine Societies |
| بيانات النشر: | Journal of the ASEAN Federation of Endocrine Societies, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_specialty, business.industry, type 2 diabetes mellitus, Endocrinology, Diabetes and Metabolism, Type 2 Diabetes Mellitus, Type 2 diabetes, dipeptidyl peptidase 4 inhibitors, Hypoglycemia, medicine.disease, Gastroenterology, Metformin, Endocrinology, Internal medicine, Statistical significance, glycemic variability, medicine, Vildagliptin, Original Article, continuous glucose monitoring, Prospective cohort study, business, premixed human insulin, Glycemic, medicine.drug |
| الوصف: | Objective. To evaluate the effect of adding DPP4 inhibitor (DPP4-I) on glycemic variability (GV) in patients with type 2 diabetes mellitus (T2DM) treated with premixed human insulin (MHI). Methodology. We conducted a prospective study in patients with T2DM on twice-daily MHI with or without metformin therapy. Blinded continuous glucose monitoring was performed at baseline and following 6 weeks of Vildagliptin therapy. Results: Twelve patients with mean (SD) age of 55.8 (13.1) years and duration of disease of 14.0 (6.6) years were recruited. The addition of Vildagliptin significantly reduced GV indices (mmol/L): SD from 2.73 (IQR 2.12-3.66) to 2.11 (1.76-2.55), p=0.015; mean amplitude of glycemic excursions (MAGE) 6.94(2.61) to 5.72 (1.87), p=0.018 and CV 34.05 (8.76) to 28.19 (5.36), p=0.010. In addition, % time in range (3.9-10 mmol/l) improved from 61.17 (20.50) to 79.67 (15.33)%, p=0.001; % time above range reduced from 32.92 (23.99) to 18.50 (15.62)%, p=0.016; with reduction in AUC for hyperglycemia from 1.24 (1.31) to 0.47 (0.71) mmol/day, p=0.015. Hypoglycemic events were infrequent and the reduction in time below range and AUC for hypoglycemia did not reach statistical significance. Conclusion. The addition of DPP4-I to commonly prescribed twice-daily MHI in patients with T2DM improves GV and warrants further exploration. |
| اللغة: | English |
| تدمد: | 2308-118X 0857-1074 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9124a44eb42c34ac9c22dc748178d99d http://europepmc.org/articles/PMC8666489 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....9124a44eb42c34ac9c22dc748178d99d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 2308118X 08571074 |
|---|